Trials / Terminated
TerminatedNCT00446329
Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Papageorgiou General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The 1st phase of the study will assess the acute biochemical response of PTH, calcium and phosphorus to orally administered doses of cinacalcet once (60mg) or twice (30mg x 2) per day. The 2nd phase of the study designed to evaluate the long term effects of cinacalcet on BMD (bone mineral density)and the levels of PTH, calcium, phosphorus as well as its ability to control secondary hyperparathyroidism without simultaneous administration of other vitamin D compounds.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | cinacalcet | Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day. |
Timeline
- Start date
- 2006-07-01
- First posted
- 2007-03-12
- Last updated
- 2014-10-29
Locations
1 site across 1 country: Greece
Source: ClinicalTrials.gov record NCT00446329. Inclusion in this directory is not an endorsement.